The Latest Breaking News from PODD

Insulet has outperformed the Nasdaq Composite over the past year and analysts remain strongly bullish about the stock’s prospects.

Despite Insulet’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Dow giant UnitedHealth is among 5 stocks holding key support while the overall market weakens.

Diabetes devices maker Insulet is the IBD Stock Of The Day as PODD stock hovers in a buy zone near its 21-day moving average.

Several stocks flashed buy signals as the market rallied heading into Fed chief Powell's speech. Here's what to expect.

Insulet is the IBD Stock Of The Day as excitement around the company's new insulin pump, Omnipod 5, drives PODD stock closer to a breakout.

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter.  According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off…

Insulet Corporation (NASDAQ:PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with DexCom Inc's (NASDAQ:DXCM) G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Related: FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients…